We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

73 hedge funds and large institutions have $493M invested in Kinnate Biopharma Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 13

6% more capital invested

Capital invested by funds: $465M → $493M (+$27.7M)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

7% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 15

4% less funds holding

Funds holding: 76 → 73 (-3)

Holders
73
Holders Change
-3
Holders Change %
-3.95%
% of All Funds
1.23%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
14
Increased
27
Reduced
13
Closed
15
Calls
$615K
Puts
–
Net Calls
+$615K
Net Calls Change
+$97K

Top Buyers

Rank Fund Capital Flow
1
LCM
Lynx1 Capital Management
Puerto Rico
+$9.14M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.97M
3
RSCM
Rock Springs Capital Management
Maryland
+$2.55M
4
BlackRock
BlackRock
New York
+$2.27M
5
NHAS
Novo Holdings A/S
Denmark
+$1.78M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$6.85M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$4.28M
3
HF
HRT Financial
New York
-$1.03M
4
Swiss National Bank
Swiss National Bank
Switzerland
-$270K
5
Two Sigma Investments
Two Sigma Investments
New York
-$259K
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
26
EcoR1 Capital
California
$2.21M – – –
Charles Schwab
27
Charles Schwab
California
$1.81M +$105K +11,241 +8%
Deutsche Bank
28
Deutsche Bank
Germany
$1.67M +$6.21K +667 +0.5%
AG
29
Artal Group
Luxembourg
$1.58M – – –
Victory Capital Management
30
Victory Capital Management
Texas
$1.5M +$302K +32,490 +38%
N
31
Nuveen
North Carolina
$1.4M +$178K +19,140 +21%
WSL
32
Western Standard LLC
California
$1.3M +$957K +102,780 New
Renaissance Technologies
33
Renaissance Technologies
New York
$1.21M +$667K +71,700 +300%
SFM
34
Sphera Funds Management
Israel
$1.16M +$853K +91,673 New
Bank of New York Mellon
35
Bank of New York Mellon
New York
$1.12M -$41.8K -4,492 -5%
Bank of America
36
Bank of America
North Carolina
$731K +$379K +40,773 +237%
GCP
37
GSA Capital Partners
United Kingdom
$711K +$85.7K +9,204 +20%
Morgan Stanley
38
Morgan Stanley
New York
$693K +$151K +16,247 +42%
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$542K +$101K +10,878 +34%
Dimensional Fund Advisors
40
Dimensional Fund Advisors
Texas
$396K +$292K +31,393 New
State Board of Administration of Florida Retirement System
41
State Board of Administration of Florida Retirement System
Florida
$243K +$180K +19,304 New
New York State Common Retirement Fund
42
New York State Common Retirement Fund
New York
$237K -$233 -25 -0.1%
JP Morgan Chase
43
JP Morgan Chase
New York
$221K -$40.6K -4,363 -20%
Barclays
44
Barclays
United Kingdom
$197K +$146K +15,652 New
MIM
45
MetLife Investment Management
New Jersey
$197K – – –
AIG
46
American International Group
New York
$172K +$8.37K +899 +7%
TI
47
Trexquant Investment
Connecticut
$169K +$125K +13,420 New
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$158K -$73.1K -7,854 -39%
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$155K +$1.82K +196 +2%
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$153K +$113K +12,130 New
1
2
3 4

KNTE Hedge Fund Activity: Q2 2022 in Review

73 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q2 2022, worth a combined $493M — up 6% from $465M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of KNTE and 14 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 27 added.

The largest buyer was Lynx1 Capital Management, adding an estimated $9.14M. The largest seller was Deerfield Management, cutting an estimated $6.85M.

  • 73 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q2 2022, down from 76 in Q1 2022.
  • Funds reported $493M of Kinnate Biopharma Inc. Common Stock stock for Q2 2022, up 6% quarter-over-quarter.
  • 14 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q2 2022 and 15 closed out, a net change of -1 holder.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q2 2022 was Lynx1 Capital Management, an estimated $9.14M added.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q2 2022 was Deerfield Management, an estimated $6.85M sold.

Based on aggregated 13F filings for Q2 2022.